Poloxamers and meroxapols were introduced to the market in the 1950s by the BASF Corp. under the names Pluronic S and Pluronic R. Poloxamers have found wide application in technology, medicine and cosmetics industry.

Bacteriophages used in therapy must be free of impurities that might cause adverse reactions e.g. endotoxins. The appropriate phage strains can be obtained and purified, for example, by the methods described in the Polish patent applications of the Institute of Immunology and Experimental Therapy PAN in Wrocław: P.348740; P 354822; P.355355; PCT/PL02/000053.

The pyrogen free bacteriophages (against Gram negative bacteria) were stored at 4 ^oC over periods of five and ten months, during which they maintained 100% of their initial lytic activity. Bacteriophages stored in culture broth at +4 ^oC lost their lytic activity insignificantly. Bacteriophages stored in a physiological saline solution lost their activity significantly after five months.

The highly purified bacteriophage preparation suffer from lack of stability. Stabilization is therefore an important problem, which we solve by addition polymers (which are accepted for use on humans).

• Legal notice:
  

  Copyright (c) Pielaszek Research, all rights reserved.
  The above materials, including auxiliary resources, are subject to Publisher's copyright and the Author(s) intellectual rights. Without limiting Author(s) rights under respective Copyright Transfer Agreement, no part of the above documents may be reproduced without the express written permission of Pielaszek Research, the Publisher. Express permission from the Author(s) is required to use the above materials for academic purposes, such as lectures or scientific presentations.
  In every case, proper references including Author(s) name(s) and URL of this webpage: https://science24.com/paper/7159 must be provided.

1. The effect of ionic strength on the aggregation of bacteriophage T4
2. Starch derivatives as vehicles for drug delivery in anticancer therapy
3. Method for determination of methotrexate (MTX) release from the macromolecular drug-carrier systems in plasma
4. Methods for determination of pemetrexed in macromolecular drug-carrier systems
5. Interaction of endotoxin and polymyxin B in B16 mouse melanoma model of metatstasis
6. ESI-MS/MS techniques for structural analysis of boron clusters
7. Methods for methotrexate determination in macromolecular conjugates drug-carrier
8. Preparation of endotoxin-free bacteriophages from bacterial lysate
9. Anticancer activity of the conjugates:  modified fibrinogen – methotrexate.
10. Antitumor activity of carrier-methotrexate conjugates.
11. Effects of phage T4 on NF-κB activity in human mononuclear cells
12. THE ANTIMETASTATIC EFFECT OF BACTERIOPHAGE T4* ADMINISTRATED IN COMBINED TREATMENT WITH SELECTED CYTOSTATICS IN MICE WITH B16 MELANOMA
13. CONJUGATES OF METHOTREXATE AND DEXTRANS IN MOUSE LEUKEMIA MODEL WITH MULTIPLE DOSE SCHEDULE